RxDoctor Payments Data

Hetal Vaishnav, MD

Ophthalmology · Melbourne, FLNPI 1750319331

Payments from drug & device makers

$1,617in general payments, 2019–2025

Across 52 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$356
  • AbbVie$341
  • Alcon$206
  • Amgen$125
  • Genentech USA, Inc.$119
  • Novartis$99
  • plus $371 from 7 others

What the payments were for

  • Food & beverage$1,53795%
  • Education$805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,617 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$2,848,765
Medicare patients
1,443
Services billed
23,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Alphagan PBrimonidine Tartrate126$47,827
RestasisCyclosporine38$43,834
LumiganBimatoprost67$37,708
RhopressaNetarsudil Mesylate73$33,540
Brimonidine Tartrate580$27,855
RocklatanNetarsudil Mesylat/Latanoprost64$25,553
IlevroNepafenac31$12,508
SimbrinzaBrinzolamide/Brimonidine Tart34$11,479
Latanoprost832$11,042
Cyclosporine15$10,014
Travoprost57$9,642
CombiganBrimonidine Tartrate/Timolol25$8,466
Prednisolone Acetate151$7,167
Atropine Sulfate133$4,086
Brinzolamide19$3,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Restasis, Lumigan, Combigan$341$137,835256 claims
NovartisIlevro$99$12,50831 claims
AlconSimbrinza$206$11,47934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →